Prophylactic melatonin significantly reduces Alzheimer’s neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPP(swe)/PS1 mice

BACKGROUND: Alzheimer’s disease (AD) underlies dementia for millions of people worldwide, and its occurrence is set to double in the next 20 years. Currently, approved drugs for treating AD only marginally ameliorate cognitive deficits, and provide limited symptomatic relief, while newer substances...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neal-Moffitt, G., Delic, V., Bradshaw, P. C., Olcese, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702331/
https://www.ncbi.nlm.nih.gov/pubmed/26159703
http://dx.doi.org/10.1186/s13024-015-0027-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702331/
https://www.ncbi.nlm.nih.gov/pubmed/26159703
http://dx.doi.org/10.1186/s13024-015-0027-6

Ejemplares similares